Objective. Previous studies have determined that depletion of serotonin reduces the severity of hind-paw inflammation in adjuvant-induced arthritis (AA) in the rat. We wished to (i) test the hypothesis that this effect may be mediated, at least in part, through a central mechanism and (ii) to investigate further the pro-inflammatory role of serotonin we determined whether increasing serotonin using a selective serotonin reuptake inhibitor (SSRI ), to increase serotonin availability at the active site of release, would increase inflammation.
A - role for serotonin (5HT ) has itis ( EAE; the model of choice for multiple sclerosis research [14] ), resides in a defect in the hypothalamobeen established in response to acute stimulation. In the rat, direct intraplantar injection of serotonin propituitary-adrenal (HPA) axis and more specifically in a lack of corticotrophin releasing factor (CRF ) duces paw oedema and a nociceptive response which can be blocked by serotonin antagonists [1] [2] [3] [4] . The responsiveness [13] . In the Piebald-Viral-Glaxo (PVG), Lewis and Wistar strains of rat, there is a effects of serotonin in chronic inflammatory conditions and its mechanism of action are less well established.
paradoxical decrease in CRF mRNA [15, 16 ] and decrease in CRF release into the hypophysial portal We have used the T-cell-mediated chronic inflammatory stress model of adjuvant-induced arthritis (AA) blood [15] , despite activation of the pituitary-adrenal components of the axis associated with inflammation which has been used for studies of arthritis, pain, inflammation and Reiter's syndrome. An upregulation in AA. Evidence suggests that arginine vasopressin takes over as the major stimulator of the axis in this in serotoninergic activity has been reported in this model with increased serotonin in plasma, spinal cord model [15, 17] . The adrenal response is crucial to survival since adrenalectomized rats exhibit an earlier and brain [5] [6] [7] [8] [9] [10] [11] . We have previously noted that wholebody depletion of serotonin using p-chlorophenylonset and greater severity of disease in AA [18] and in EAE [19] . Left untreated, the outcome is rapidly alanine (PCPA; a reversible inhibitor of tryptophan hydroxylase) at the time of onset of inflammation, but fatal, although this can be prevented with steroid replacement. not at the time of adjuvant injection, reduces the severity of hind-paw inflammation [12] , confirming a
In the present study, we have addressed three questions: (i) is central serotonin involved in modulating pro-inflammatory role for serotonin in this model. These studies offer little insight as to the site of action the degree of inflammation in this model; (ii) on the basis of the pro-inflammatory actions of serotonin, of serotonin, which could be directly at the level of the joint, through modulation of the immune system, or would using a selective serotonin reuptake inhibitor (SSRI ) result in an earlier onset and/or increased centrally.
Profound neuroendocrine changes are associated severity of inflammation; (iii) does manipulation of serotonergic systems alter the HPA axis? with the development of immune-mediated disease in humans and in animal disease models. It has been suggested that a component determining susceptibility METHODS in autoimmune disease models such as experimental Nine-week-old male PVG rats (Harlan-Olac, UK ) arthritis [13] and experimental allergic encephalomyelwere housed four to a cage under standard environmental conditions with free access to food and water. On day 0, the rats were given a single intradermal heat-killed Mycobacterium butyricum in paraffin oil Palkovits and Brownstein [24] . These were processed for determination of serotonin and the major serotonin into the base of the tail. Inflammation is usually first apparent at around day 13/14 and, following consultametabolite 5-hydroxyindole acetic acid (5-HIAA) by high-performance liquid chromatography (HPLC ) tion with the Home Office Animal Inspectorate, experiments are terminated within 24 h of evidence of hindwith electrochemical detection as described previously [25] . Briefly, tissues were placed in cold 0.2  acetic paw inflammation, usually day 14. At this time, animals were decapitated, and the brains and pituitaries rapidly acid and immediately frozen on dry-ice. After thawing, they were centrifuged at 19 000 g for 3 min at 4°C. removed and frozen on dry-ice. The brains were taken for determination of serotonin concentrations in Twenty microlitres of the supernatant were assayed for serotonin and 5-HIAA content. The pellets were resusspecific nuclei and/or for CRF mRNA in the paraventricular nucleus (PVN ), and the pituitaries were taken pended in 0.2  NaOH and assayed for protein content using Pierce protein reagent (Pierce & Warrinder, for pro-opiomelanocortin (POMC ) mRNA determination by in situ hybridization histochemistry. FortyChester) with bovine serum albumin as standard. Hind paws were collected into 4% formaldehyde and paw eight-base 35S-labelled oligonucleotide probes complementary to part of the exonic mRNA sequences coding volume determined as described above. Sections of 12 mm through the PVN and anterior pituitary were for CRF or POMC mRNAs were used as described previously [20, 21] The in vivo 5HT uptake inhibitory potency occurs at lower doses compared to NA and DA uptake inhibichange from control ± ...
Trunk blood was taken for plasma corticosterone tion, demonstrating potent and selective 5HT reuptake inhibition [26 ] . The SSRI was chosen precisely because measurements by radioimmunoassay using antiserum supplied by Dr G. Makara (Institute of Experimental it is a very selective SSRI with little effect on catecholaminergic systems, which does not appear to be the case Medicine, Budapest, Hungary). The tracer was [125I ]corticosterone (ICN Biomedicals, CA, USA) with with other SSRIs, e.g. Prozac [27] . Ten days after injection of the adjuvant, and prior to the development a specific activity of 2-3 mCi/mg. The sensitivity of the assay was 25 ng/ml. The intra-assay coefficient of variof inflammation, control and adjuvant-injected animals received an injection (i.p.) of either vehicle or ation was <12%.
Hind paws were collected into 4% formaldehyde and Lu10-134 (10 mg/kg). This was repeated on days 11 and 12. Brains, pituitaries, plasma and paws were the degree of inflammation measured by plethysmometry ( Ugo-Basile, Milan, Italy) to provide an index of collected on day 13 after adjuvant injection (due to the earlier onset and severity of inflammation seen at severity. Hind paws were submerged to the level of the lateral malleolus and the mean of three recordings this time), and processed as described above. taken. Measurements were accurate to 0.01 ml.
Statistics Statistical comparisons were made between groups 5∞7∞-Dihydroxytryptamine neurotoxin lesioning
Six days after injection of adjuvant, the animals using the Fisher PLSD test following one-way analysis of variance. A value of P < 0.05 was considered were anaesthetized using sodium pentabarbitone and injected i.p. with desipramine hydrochloride (Sigma, significant. Poole) at a dose of 25 mg/kg to prevent damage to RESULTS catecholaminergic neurons. Thirty minutes later, 10 ml of vehicle (0.9% saline containing 1 mg/ml ascorbic 5∞7∞-Dihydroxytryptamine neurotoxin lesioning The development of inflammation did not alter acid) or 5∞7∞-dihydroxytryptamine creatinine sulphate (150 mg free base, Sigma, Poole) were infused into the concentrations of either serotonin or 5-HIAA in the CeA, hippocampus or VMN compared with levels in right lateral ventricle. On day 14, the animals were decapitated, trunk blood collected and plasma stored sham-lesioned controls ( Table I ) . Following 5∞7∞-dihydroxytryptamine lesions, there were highly signiat −20°C. Brains and pituitaries were collected, quickly frozen on dry-ice and stored at −80°C.
ficant (>90%) reductions in both serotonin and 5-HIAA levels in the areas investigated, with no differSections (3 × 300 mm) were taken through the hippocampus, central amygdala (CeA) and ventromedial ence between the adjuvant-injected and control rats. Fourteen days after adjuvant injection, vehiclehypothalamic nucleus ( VMN ). Micropunches of each of these areas were taken according to the atlas of infused rats had developed hind-paw inflammation, as 53.3 ± 11.9** 344.7 ± 69.9** 154 ± 70** AA ± 5∞7∞-DHT 96.7 ± 9.9 222.9 ± 54.3* 189 ± 40** **P < 0.01 and *P < 0.05 compared with control levels.
decreased levels of CRF mRNA in the PVN and the increased hind paw inflammation. POMC mRNA in the anterior pituitary was not altered by serotonin ventricle. Fourteen days after adjuvant injection, the hind paws were collected and measured. Serotonin depletion had no effect on paw volume in the non-adjuvant-injected animals. AA rats had signific-
Treatment with SSRI
antly increased paw volume which was reduced by serotonin deple-
In the second study, adjuvant-injected rats or contion. **P < 0.01 against control; § §P < 0.01 against AA+ lesion.
trols were treated with a daily injection of an SSRI or
Values represent means with ... for n = 7-9 per group.
vehicle beginning 10 days after adjuvant injection and prior to any visible signs of inflammation. Treatment with the SSRI produced an earlier onset of inflammaexpected in this model (Fig. 1) . The serotonin-depleted animals had significantly reduced inflammation at this tion with visible hind-paw swelling clearly apparent in all nine animals in this group at day 12, one day prior time. Indeed, only two of the nine animals in this group exhibited a significant degree of swelling in their to the expected time of onset. No animals in the vehicle-injected AA group had inflammation at this hind paws.
The changes in the HPA axis are summarized in time. In accordance with the Home Office guidelines, the study was terminated on day 13. At this time, the Table II. Depletion of serotonin had no effect on CRF mRNA levels in the PVN. Associated with inflammavehicle-injected AA rats had a significant (P < 0.01) hind-paw inflammation (Fig. 2) . The SSRI-treated rats tion, there was a significant decrease in CRF mRNA. In the lesioned, adjuvant-injected animals, CRF had significantly (P < 0.01) increased inflammation compared with vehicle-injected AA rats. mRNA levels were not significantly different from control levels and significantly increased from those Treatment with the SSRI had no effect on CRF mRNA in the PVN, POMC mRNA in the anterior in sham-operated AA rats. There was a significant (P < 0.001) negative correlation (r = −0.681) between pituitary or circulating levels of corticosterone supporting our contention of a role for central serotonin in modifying peripheral inflammation. The complicated nature and the multiple receptor subtypes (at least 15 to date) which comprise the serotoninergic system have confounded analysis of the role of serotonin. While some insight has been gained through the use of serotonin receptor antagonists, the relative lack of specificity of these compounds has made interpretation difficult. Thus, antagonists directed against the serotonin -1, -2 and -3 receptor subtypes have been shown to be beneficial in reducing acute inflammation in a number of animal studies [3, 10, 28, 29, 30] . In contrast to these reports, others have reported an exacerbation of inflammatory disease activity following treatment with serotonin antagonists [28, 31] . These discrepancies are likely to be due to differential specificities of the drugs used and the different receptor subtypes involved. An alternative with the SSRI increase the severity of the inflammation, AA ± SSRI 46.3 ± 3.5** 178.1 ± 11.9** 187 ± 23** but there was also a very rapid onset within 2 days of beginning treatment with the SSRI. Using the AA **P < 0.01 compared with control levels.
model, we have consistently observed the onset of inflammation on day 13 with a termination of the experiments on day 14 when all the animals have ( Table III ) . Increased levels of POMC mRNA in the anterior pituitary and of plasma corticosterone in the inflamed hind paws. In contrast, in this study, we observed an earlier onset of inflammation which was AA group were not altered by SSRI treatment. Similarly, the decrease in CRF mRNA seen in rats apparent by day 12 in all the SSRI-treated animals. As noted previously, there was no evidence of hindwith AA was also not altered by treatment with the SSRI.
paw inflammation in the vehicle-treated animals. Because of the earlier onset of inflammation in the DISCUSSION SSRI-treated rats, the experiment was terminated on day 13 when the vehicle-injected rats were exhibiting Central depletion of serotonin resulted in a significant reduction in hind-paw inflammation compared a mild inflammation compared with the significantly increased inflammation of the SSRI-treated animals at with vehicle-injected controls. These data confirm our previous report demonstrating a reduction in severity this time. This demonstrates in this model that treatment with an SSRI at around the time of onset of of inflammation following total body serotonin depletion and confirm a pro-inflammatory role for serotonin clinical symptoms increases the severity of inflammation. In the light of these observations, the role of in AA [12] . Furthermore, we extend our original observations to suggest that this inflammatory effect SSRIs in increasing inflammation in humans needs to be addressed. It is possible that these effects would be of serotonin is mediated, at least in part, through a central mechanism. Centrally injected serotonin has manifest before any effects of these drugs on mood would be apparent and could easily be overlooked in previously been determined to influence the severity of inflammation in an acute paw oedema model [28] , the clinical setting.
In order to determine a possible locus of action survival and, in particular, the ability to mount a glucocorticoid response to either acute injection of for serotonin, we measured levels of serotonin and the major metabolite 5-HIAA in the VMN, CeA cytokines or immune modulators such as lipopolysaccharide (LPS ), or following the development of and hippocampus in vehicle-injected and serotonindepleted animals. AA did not alter concentrations of clinical symptoms in autoimmune disease models such as AA and EAE [18, 19, 41] . In the present study, we either of these compounds in any of the areas investigated. We have previously reported no change in noted a significant decrease in CRF mRNA in the vehicle-injected AA rats, which is in accord with previserotonin levels in the PVN of the hypothalamus in rats with inflamed hind paws [12] . Together, these data ous reports [15, 16 ] . In the serotonin-depleted adjuvant-injected rats, which did not show an increase in suggest that these four areas, known to receive serotoninergic inputs and implicated in aspects of the neural hind-paw volume, no decrease in CRF mRNA was observed. Indeed, a good inverse correlation between response to stress, acute inflammation and behaviour, may not be involved in mediating the pro-inflammatory the decrease in CRF mRNA and the increase in paw volume was observed in this study. Such a relationship effects of serotonin in this chronic inflammatory stress model. Reports in the literature suggest differences in has been noted previously [12, 42] and supports the notion of a non-glucocorticoid-mediated mechanism serotonin metabolism within the brain in AA, but in these studies relatively large areas were dissected for responsible for the downregulation of CRF mRNA influenced by the severity of inflammation [18] . analysis, such as 'forebrain' or 'hypothalamus plus midbrain' [5, 7] , making it difficult to assess the precise Evidence suggests a role for substance P in mediating this inhibitory effect on the CRF neuron [43] . POMC location of these changes and the brain nuclei involved. Further investigation will be required to ascertain the mRNA was significantly increased in the AA rats, as has been noted previously [15, 39, 40] . Plasma corticocentral site(s) of action of serotonin in mediating alterations in the severity of hind-paw inflammation in sterone concentrations were increased in the serotonindepleted rats despite the lack of effect of serotonin this model. Serotonin, particularly in the hippocampus, which depletion on either CRF mRNA in the PVN or POMC mRNA in the anterior pituitary. We have previously expresses a wide variety of serotonin receptors, has been implicated as a potential neuroimmunomodulator made a similar observation in PCPA-treated rats where plasma corticosterone levels were increased in the providing a link between the nervous and immune systems. This may represent a mechanism whereby absence of any elevation in plasma ACTH or CRF mRNA in the PVN [22] , suggesting an action on serotonin can exert these pro-inflammatory effects. Serotonin is able to stimulate expression of a number corticosterone release, perhaps mediated via arginine vasopressin as noted previously [17, 18] , rather than of cytokine mRNAs, such as interleukin (IL)-6, tumour necrosis factor alpha and transforming growth factor through an action on CRF neurons. In non-arthritic animals, treatment with the SSRI beta in rat hippocampal astrocytes [33] . These cytokines have been implicated in inflammatory processes. on days 10, 11 and 12 had no effect on levels of CRF mRNA in the PVN, POMC mRNA in the anterior In addition to the effects of serotonin on cytokine mRNA expression, the converse is also true in that pituitary or circulating levels of corticosterone on day 13. In contrast in AA animals, levels of CRF mRNA administration of IL-1 and IL-6 is able to increase serotonin turnover in the hippocampus and other brain in the PVN were reduced and levels of POMC mRNA in the anterior pituitary and corticosterone were areas [34] [35] [36] [37] , where this increased turnover is likely to be involved in the behavioural changes associated increased as noted previously [15, 18, 40, 44] . These levels were not significantly affected by SSRI treatment with cytokine administration [37] . In contrast, serotonin may not be involved in mediating the effects of despite the effects on disease. It appears likely, therefore, that the SSRI may be exerting its proacute cytokine administration on the response of the HPA axis as we found no difference in the activation inflammatory actions independently of the HPA axis. This is intriguing as we have previously seen good of the HPA axis in response to icv IL-1b following total body depletion of serotonin using PCPA [38] .
correlations between changes in the HPA axis associated with increased inflammation. These data suggest the possibility of different serotonin pathways mediating responses to different acute stimuli Together, these data support a pro-inflammatory role for serotonin in this chronic inflammatory stress and also between acute and chronic stimuli.
One possible mechanism involved in determining the model and suggest that these actions are mediated, at least in part, through a central mechanism. Thus, the susceptibility and/or severity of inflammation is the HPA axis. There are profound neuroendocrine changes data provide further evidence for the proposition that manipulation of central neurotransmitter systems can associated with the development of immune-mediated disease, such as increased circulating levels of adrenoinfluence the course of peripheral inflammation [28, 42] . Furthermore, the evidence suggests that acute corticotrophic hormone (ACTH ) and corticosterone and increased POMC mRNA in the anterior pituitary treatment with SSRIs may exacerbate the development of peripheral inflammation. The mechanism of action [15, 39, 40] . This activation occurs despite the paradoxical decrease in CRFergic activity seen in this model. and the receptor subtypes involved in mediating these effects, particularly at the central level, remain to be Previous studies have demonstrated the fundamental importance of a functioning HPA axis to an organism's determined. Overall, these data suggest that serotonin
